Adomeglivant

Adomeglivant

CAT N°: 29668
Price:

From 48.00 40.80

Adomeglivant is an allosteric antagonist of the glucagon receptor.{47796,47797} It inhibits glucagon-induced increases in cAMP levels in HEK293 cells expressing the rat glucagon or GLP-1 receptors (IC50s = 1.8 and 1.2 µM, respectively) but has no effect on cAMP levels when used alone.{47797} Adomeglivant also inhibits increases in cAMP levels induced by GLP-1 or exendin-4 (48-86) amide (Item No. 11096) in HEK293 cells expressing the GLP-1 receptor (IC50s = 7 and 12 µM, respectively). It decreases glucose-stimulated insulin secretion when used at a concentration of 1 µM in combination with the GLP-1 receptor antagonist exendin (9-39) in isolated human islets but not glucose-stimulated glucagon secretion when used alone or in combination with exendin (9-39) in isolated mouse islets.{47798}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-[(1S)-1-[[4?-(1,1-dimethylethyl)-2,6-dimethyl[1,1?-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]-?-alanine
  • Correlated keywords
    • 872260-20-3 LY 2409021 HEK 293 GLP1
  • Product Overview:
    Adomeglivant is an allosteric antagonist of the glucagon receptor.{47796,47797} It inhibits glucagon-induced increases in cAMP levels in HEK293 cells expressing the rat glucagon or GLP-1 receptors (IC50s = 1.8 and 1.2 µM, respectively) but has no effect on cAMP levels when used alone.{47797} Adomeglivant also inhibits increases in cAMP levels induced by GLP-1 or exendin-4 (48-86) amide (Item No. 11096) in HEK293 cells expressing the GLP-1 receptor (IC50s = 7 and 12 µM, respectively). It decreases glucose-stimulated insulin secretion when used at a concentration of 1 µM in combination with the GLP-1 receptor antagonist exendin (9-39) in isolated human islets but not glucose-stimulated glucagon secretion when used alone or in combination with exendin (9-39) in isolated mouse islets.{47798}

We also advise you